ARCHIVES

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

This article is from The Cancer Letter archive.

Vol. 20 No. 33 | August 19, 1994

Download PDF Visit The Full Archive

Related Articles

Estrogen Can Benefit Women With Metastatic Breast Cancer

January 30, 2009

O’Connor Is New NS President, Curtiss Is Next

May 24, 1991

Group Chairmen Reject DCT’s Agenda For Clinical Trials Review, demand Right To Select Speakers

June 30, 1978

NTP Panel Completed To Write New Testing, Evolution Guidelines

April 22, 1983

Advisors Call for External Oversight, Coordination of NCI Clinical Trials.

February 25, 2005

R01 and P01 Grants Will No Longer Support Phase III Clinical Trials

July 25, 2013